~ JN will lead bio-industry in the next generation
Each year, millions of children
and adults die and suffer from diseases and disorders that could
be prevented by current and future vaccines. JN-International
investing to accelerate the development and introduction of
appropriate and affordable vaccines in impoverished countries.
Starting with a vaccines to prevent Meningococcal
meningitis, Stroke, Hepatitis C, Herpes, Tuberculosis - the
largest causes of deaths around the world - the current efforts
on JN promise to create for these vaccines for the nations
around the world.
Products
JN is one of the leading vaccine innovative
corporation of 21st Century, JN's growing popularity
in developing world to meet some of the world's most
urgent medical needs.
Phase 3 trials of Meningococcal meningitis A,CY,W-135 plain polysaccharide vaccine trials
were successfully completed in sub-Sharon Africa (Niger and
Burkina Faso) using 750
people. Immunogenicity and protection described in
the product insert.
Meningococcal groups A C
Y and W-135 DT conjugate vaccines were developed using a
genetically detoxified Diphtheria Toxoid as the protein
carrier
Phase 3 trial is
successfully completed and approved by Ministry of
Health of Côte
d'Ivoire in North Ivory Coast using
100 sero-negative male and female volunteers.
Protective sero-conversion
recorded in 98% individuals tested by Institute Pasture
Research Institute in Ivory Coast.
Diphtheria Toxoid was
chosen for low-cost vaccine production.
The vaccine had a
tremendous impact on the incidence of the disease,
resulting in a more than 90% decrease in the number of
deaths and clinical cases, and a 66% decrease in
asymptomatic carriage (cf. WHO) in sub-Saharan Africa.
"At present, our corporation has been
planning to construct vaccine manufacture facility in Côte
d'Ivoire or in Burkina Faso ( in 2010-11) for easy
access and quick supply of plain and conjugate vaccines
to sub-Sharon Africa to deal with frequent Meningitis
out breaks in the region."
Mobile Clinics models
Vaccine
Discovery
JN's Research Facilities are in
the discovery, development, and clinical
evaluation of vaccine products for
vaccine-preventable diseases.
This first stage of stroke clinical trials is designed to gain basic safety and pharmacologic information. Single or multiple conservative doses of the drug will be administered to volunteers. Analysis of these studies allow JN to assess the drug’s mechanism of action in humans, pharmacology, pharmacokinetics, side effects of various doses, safe dosage range, and the optimal route of administration. Animal model experiments using pigs were successfully proved that the vaccine can can protect and cure the Endothelia-1 induced MCA occlusion in experimental pigs with no side effects or damage to vital organs. Memory related aspects in vaccination and treated pigs still under evaluation by
"Hippocampal Retrieval of Food-Flavor Memory in Experimental Pigs"., unless and until this parameter is proved to be successful, the project cannot move to human trials.
The current invention draws scope of newer methodologies in the development of vaccine against Hepatitis C virus genotype-1a and b on the basis of phylogenetic analysis of nucleotide sequences of NS3/NS4a genes of multiple genotypes and subtypes of Flaviviruses. The immunization of r-NS3/NS4a protein or DNA induced humoral and cell mediated protective immune response against Hepatitis C viruses 1a and 1b in mouse models and not sure how it works for human? unless we go for Phase 1 in 2008.
Meningococcal
A.C.Y.W-135 polysaccharide vaccine
